)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Solid Biosciences
Solid Biosciences (SLDB) investor relations material
Solid Biosciences Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary12 Feb, 2026
Company overview and strategic focus
Focuses on precision genetic medicine, primarily gene therapies, with three lead programs targeting Duchenne muscular dystrophy (DMD), Friedreich's ataxia (FA), and CPVT, plus additional pipeline assets and a proprietary capsid platform.
Emphasizes innovation in gene therapy delivery, including capsids, promoters, dual plasmids, and manufacturing purity to improve investability and outcomes.
Employs about 120 staff and collaborates with over 50 academic labs and small companies, aiming to expand partnerships further.
DMD program and regulatory progress
Achieved alignment with the FDA on a registration study for DMD, seeking accelerated approval in the US, with a large safety database and over 36 patients dosed to date.
No significant safety signals observed so far, including no drug-induced liver injury or myocarditis among the first 36 patients.
Double-blind, placebo-controlled trial for DMD in boys aged 7–11 is set to begin dosing within 90 days, with the first patient already screened and a second lined up.
Trial design incorporates FDA guidance, with time to rise as a primary endpoint and an 18-month assessment period to allow for meaningful clinical change.
Method of steroid administration was optimized based on early trial learnings, leading to method-of-use patent filings.
Differentiation and innovation in gene therapy
SGT-003 features a novel capsid with rapid, targeted muscle transduction and quick clearance from blood, reducing safety risks compared to earlier vectors.
The construct includes additional proteins (nNOS, alpha-syntrophin, caveolin-4) for improved efficacy and cardiac protection.
Manufacturing process achieves a high full-to-empty capsid ratio, enhancing expression and safety.
Ease of use and reduced physician burden are expected to drive adoption, as current therapies require complex monitoring and additional drugs.
SGT-003: How will ease of use drive adoption?
SLB101 steroid dosing: What are patent implications?
FA program: Rationale for dual-route administration?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Solid Biosciences earnings date
Q4 20256 Mar, 2026
Solid Biosciences
Next Solid Biosciences earnings date
Q4 20256 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Solid Biosciences Inc. is a life science company dedicated to developing therapies for neuromuscular and cardiac diseases. The company's primary focus includes advancing a portfolio of gene therapy candidates for various conditions, such as Duchenne muscular dystrophy with its lead product candidate SGT-003, Friedreich's ataxia treated by AVB-202-TT, and BAG3-mediated dilated cardiomyopathy with AVB-401. Solid Biosciences is also working on developing platform technologies that include dual gene expression, allowing for the packaging of multiple transgenes into one vector, and the exploration of novel capsids. The company's mission is driven by a commitment to improve the daily lives of patients living with these debilitating diseases, supported by collaborations and partnerships, including a notable agreement with Ultragenyx Pharmaceutical Inc. for the development and commercialization of new gene therapies for Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage